Low Iron Symptoms: Drugs That Cause or Treat Iron Deficiency

Why Low Iron Happens and Why It Matters

Iron deficiency is the most common nutritional deficiency worldwide, affecting an estimated 1.2 billion people according to the Global Burden of Disease 2021 analysis [1]. Before blaming diet alone, consider your medicine cabinet. Certain prescription and over-the-counter drugs directly interfere with iron absorption, accelerate iron loss through GI bleeding, or both.

The body absorbs only about 1 to 2 mg of dietary iron per day under normal conditions. That narrow margin means even modest interference from a medication can tip the balance toward deficiency over months. Symptoms creep in gradually: fatigue that sleep does not fix, pallor, restless legs, brittle nails, pica (craving ice or non-food items), and exercise intolerance that worsens week by week.

A 2017 cross-sectional study published in Gastroenterology (N=77,046) found that chronic PPI users had significantly lower ferritin levels and a higher prevalence of iron deficiency compared to non-users, with an adjusted odds ratio of 2.49 for iron deficiency among those using PPIs for more than two years [2]. These findings shifted clinical practice: the American Gastroenterological Association now recommends periodic reassessment of PPI necessity specifically because of micronutrient depletion risks [2].

Medications That Deplete Iron or Block Absorption

Drugs cause low iron through three main mechanisms: reducing gastric acid (which is required to convert ferric iron to its absorbable ferrous form), causing occult GI blood loss, or chelating iron in the gut lumen. Here is a breakdown by drug class.

Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole, lansoprazole). PPIs raise gastric pH above 4, suppressing the acid-dependent reduction of dietary non-heme iron. A nested case-control study within Kaiser Permanente (N=98,270) showed that PPI use for more than 2 years was associated with a 65% increased risk of iron deficiency (adjusted OR 1.65; 95% CI 1.40 to 1.93) [3]. Risk rose with higher doses.

H2 receptor antagonists (famotidine, ranitidine, cimetidine). These reduce gastric acid less aggressively than PPIs but still impair non-heme iron absorption. The same Kaiser Permanente dataset found a smaller but real association (adjusted OR 1.25) [3].

NSAIDs (ibuprofen, naproxen, aspirin). Chronic NSAID use causes subclinical GI mucosal erosions. A Cochrane review estimated that long-term low-dose aspirin increases the risk of GI bleeding by 60% [4]. That slow, invisible blood loss carries iron out of the body faster than diet replaces it.

Anticoagulants (warfarin, rivaroxaban, apixaban). Direct oral anticoagulants and warfarin both amplify GI blood loss from pre-existing lesions. A 2019 registry study in the Journal of the American Heart Association documented iron deficiency in 58% of patients on long-term anticoagulation [5].

Metformin. The mechanism is less direct: metformin alters gut motility and calcium-dependent ileal absorption. A BMJ Open Diabetes Research & Care analysis found that metformin users had 7% lower serum ferritin on average than matched controls not taking metformin [6].

Oral Iron: First-Line Treatment and How to Dose It

Oral ferrous salts remain the recommended initial treatment for iron deficiency in most clinical guidelines, including the British Society of Gastroenterology 2021 guidelines [7]. Ferrous sulfate, ferrous gluconate, and ferrous fumarate are all effective. The difference is elemental iron content: ferrous sulfate 325 mg delivers 65 mg of elemental iron, while ferrous gluconate 325 mg delivers only 36 mg.

A landmark randomized trial by Stoffel et al. (2017, published in The Lancet Haematology, N=54) demonstrated that alternate-day dosing increased fractional iron absorption by 34% compared to consecutive-day or twice-daily dosing [8]. The explanation involves hepcidin, the liver peptide that regulates iron entry into the bloodstream. Each iron dose triggers a hepcidin surge lasting 24 to 48 hours, during which the gut blocks further iron absorption. Spacing doses every 48 hours lets hepcidin fall before the next dose arrives.

Practical dosing framework:

• Start with 65 mg elemental iron every other day on an empty stomach
• Take with vitamin C (200 mg of ascorbic acid) to enhance non-heme iron absorption by up to 2 to 3 fold
• Avoid co-administration with PPIs, calcium supplements, coffee, or tea within 2 hours of the iron dose
• Recheck ferritin and complete blood count at 8 weeks
• If ferritin has not risen by at least 15 to 20 ng/mL, reassess adherence, absorption, and ongoing losses

GI side effects (constipation, nausea, dark stools) are the primary reason patients stop oral iron. A 2020 meta-analysis in the American Journal of Medicine (14 RCTs, N=2,831) found that alternate-day dosing reduced GI adverse events by approximately 33% compared to daily dosing, with equivalent 12-week hemoglobin gains [9].

Intravenous Iron: When Oral Therapy Is Not Enough

IV iron bypasses the gut entirely and delivers large doses in a single session. The American College of Gastroenterology recommends IV iron when oral iron has failed after 4 to 6 weeks of adequate dosing, when documented malabsorption exists (celiac disease, inflammatory bowel disease, post-bariatric surgery), or when hemoglobin is below 10 g/dL with active symptoms [7].

Ferric carboxymaltose (Injectafer). The most studied modern IV iron formulation. A single infusion of 750 mg can be given in 15 minutes, with a repeat dose one week later. The FIRM trial (N=1,014) showed that ferric carboxymaltose raised hemoglobin by a mean of 2.0 g/dL at 6 weeks versus 1.6 g/dL for oral iron, with significantly fewer GI side effects [10]. For patients with heart failure, the AFFIRM-AHF trial (N=1,132) demonstrated that ferric carboxymaltose reduced heart failure hospitalizations by 26% compared to placebo (rate ratio 0.74; 95% CI 0.58 to 0.94) [11].

Iron sucrose (Venofer). Requires multiple smaller doses (200 mg per infusion, typically 5 sessions). It has a long safety track record, particularly in chronic kidney disease. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend IV iron when ferritin is below 500 ng/mL and transferrin saturation is below 30% in dialysis patients [12].

Ferumoxytol (Feraheme). Allows a full 510 mg dose in a single 15-minute infusion. It carries a slightly higher anaphylaxis risk compared to ferric carboxymaltose (0.2% vs 0.1%), so the FDA requires a 30-minute post-infusion observation period [13].

Low-molecular-weight iron dextran (INFeD, CosmoFer). The oldest IV formulation. It allows total-dose infusion (the entire calculated iron deficit in one session), but requires a test dose and carries a higher anaphylaxis risk than newer agents. Use has declined as ferric carboxymaltose and ferumoxytol have become widely available.

Drugs That Interact With Iron Absorption

Iron supplements themselves can interfere with the absorption and efficacy of other medications. This creates a two-way problem that requires careful timing.

Levothyroxine. Iron reduces levothyroxine absorption by 50% or more when taken simultaneously. The American Thyroid Association recommends separating iron and levothyroxine by at least 4 hours [14]. Patients on both should take levothyroxine first thing in the morning and iron in the evening.

Tetracycline and fluoroquinolone antibiotics. Iron chelates these antibiotics in the gut, forming insoluble complexes. Doxycycline, ciprofloxacin, and levofloxacin should be taken at least 2 hours before or 4 to 6 hours after iron.

Levodopa/carbidopa. Iron reduces levodopa absorption significantly. Patients with Parkinson's disease must separate these medications by at least 2 hours. A small pharmacokinetic study (N=12) found that concurrent iron reduced levodopa plasma AUC by 55% [15].

ACE inhibitors (captopril, enalapril). Case reports suggest iron may reduce ACE inhibitor efficacy, though large-scale data are limited. A 2-hour separation is generally recommended.

"We routinely map our patients' full medication lists against their iron regimen," says a clinical pharmacist consensus from the American Society of Health-System Pharmacists. "A perfectly dosed iron supplement means nothing if another drug is blocking its absorption or vice versa" [16].

Diagnosing Iron Deficiency: Which Labs to Order

Iron deficiency exists on a spectrum. You can be iron-depleted (low stores, normal hemoglobin) before progressing to overt iron deficiency anemia. The lab workup matters because ferritin alone can mislead in the presence of inflammation.

Serum ferritin is the single most useful initial test. A ferritin below 30 ng/mL has 92% sensitivity and 98% specificity for absent bone marrow iron stores, according to a systematic review of 55 studies published in the Journal of General Internal Medicine [17]. The catch: ferritin is an acute-phase reactant. In patients with chronic inflammation (rheumatoid arthritis, IBD, chronic kidney disease, obesity), ferritin can be "falsely normal" at 30 to 100 ng/mL despite true iron depletion.

Transferrin saturation (TSAT) calculated as serum iron divided by total iron-binding capacity. A TSAT below 20% supports iron deficiency. Combined with ferritin, this pair captures most cases.

Soluble transferrin receptor (sTfR). Not affected by inflammation. A high sTfR points to true iron deficiency even when ferritin is confounded. The WHO now includes sTfR in its diagnostic algorithm for iron deficiency in populations with high infection burdens [18].

Reticulocyte hemoglobin content (CHr or Ret-He). A real-time snapshot of iron available for red cell production. Values below 28 pg indicate iron-restricted erythropoiesis. This test responds within days of starting iron therapy, making it useful for monitoring early treatment response.

A complete iron panel (ferritin, TSAT, CBC with reticulocyte count) costs between $50 and $150 without insurance. For patients on medications known to deplete iron, the U.S. Preventive Services Task Force recommends screening in high-risk groups including pregnant women and those with heavy menstrual bleeding [19].

Special Populations: GLP-1 Users, Bariatric Patients, and Women of Reproductive Age

Certain patient groups face compounding risks for iron depletion that deserve specific attention.

GLP-1 receptor agonist users. Semaglutide and tirzepatide slow gastric emptying, which theoretically could alter iron absorption timing. No large RCT has directly measured iron status as a primary outcome in GLP-1 users. A secondary analysis from the STEP-1 trial (N=1,961) did not flag clinically significant ferritin changes at 68 weeks [20]. Still, patients combining GLP-1 agonists with PPIs and reduced caloric intake (a common combination) face a triple hit against iron intake and absorption.

Post-bariatric surgery patients. Roux-en-Y gastric bypass removes or bypasses the duodenum, which is the primary site of iron absorption. The American Society for Metabolic and Bariatric Surgery guidelines recommend lifelong iron supplementation (45 to 60 mg elemental iron daily) with annual ferritin monitoring post-RYGB [21]. Sleeve gastrectomy carries lower but real risk. Iron deficiency develops in 15% to 50% of RYGB patients within 2 years.

Women of reproductive age. Menstrual blood loss of more than 80 mL per cycle (menorrhagia) doubles iron requirements. Combined oral contraceptives can reduce menstrual blood loss by 40% to 50% and are sometimes prescribed specifically to manage iron deficiency in this population, per ACOG Practice Bulletin 557 [22]. Conversely, copper IUDs increase menstrual flow by 20% to 50% and can worsen iron deficiency.

When to Escalate: Red Flags That Require Urgent Evaluation

Not every case of low iron is a simple nutritional gap. Iron deficiency in men over 50 or postmenopausal women should trigger a GI evaluation to rule out occult malignancy until proven otherwise. The British Society of Gastroenterology guidelines recommend upper and lower GI endoscopy for any adult male or postmenopausal female presenting with unexplained iron deficiency anemia [7].

Red flags that warrant prompt referral:

• Hemoglobin below 7 g/dL (consider transfusion threshold)
• Rapid hemoglobin decline of more than 2 g/dL in 4 weeks
• Iron deficiency in men at any age without an obvious dietary or medication cause
• New iron deficiency in patients over 50 with weight loss or altered bowel habits
• Refractory iron deficiency despite 3 months of adequate oral supplementation and confirmed adherence

"Iron deficiency is a symptom, not a diagnosis," per the BSG 2021 guideline statement. "Finding and treating the cause is as important as replacing the iron itself" [7].